{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:47:36Z","timestamp":1761518856615},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1007\/s11864-005-0043-9","type":"journal-article","created":{"date-parts":[[2007,7,4]],"date-time":"2007-07-04T18:52:03Z","timestamp":1183575123000},"page":"397-409","source":"Crossref","is-referenced-by-count":18,"title":["Advances in the treatment of neuroendocrine tumors"],"prefix":"10.1007","volume":"6","author":[{"given":"Matthew","family":"Kulke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"43_CR1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2","volume":"79","author":"I Modlin","year":"1997","unstructured":"Modlin I, Sandor A: An analysis of 8305 cases of carcinoid tumors. Cancer 1997, 79: 813\u2013829.","journal-title":"Cancer"},{"key":"43_CR2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3109\/02841868909111217","volume":"28","author":"K Oberg","year":"1989","unstructured":"Oberg K, Eriksson B: Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncol 1989, 28: 425\u2013431.","journal-title":"Acta Oncol"},{"key":"43_CR3","first-page":"322","volume":"84","author":"T Berge","year":"1976","unstructured":"Berge T, Linnell F: Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand 1976, 84: 322\u2013330.","journal-title":"Acta Pathol Microbiol Scand"},{"key":"43_CR4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0025-6196(12)62083-7","volume":"66","author":"FJ Service","year":"1991","unstructured":"Service FJ, McMahon MM, O\u2019Brien PC, Ballard DJ: Functioning insulinoma\u2014incidence, recurrence, and longterm survival of patients: a 60-year study. Mayo Clin Proc 1991, 66: 711\u2013719.","journal-title":"Mayo Clin Proc"},{"key":"43_CR5","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199504273321707","volume":"332","author":"FJ Service","year":"1995","unstructured":"Service FJ: Hypoglycemic disorders. N Eng J Med 1995, 332: 1144\u20131152.","journal-title":"N Eng J Med"},{"key":"43_CR6","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/BF01655532","volume":"10","author":"PN Goode","year":"1986","unstructured":"Goode PN, Farndon JR, Anderson J, et al.: Diazoxide in the management of patients with insulinoma. World J Surg 1986, 10: 586\u2013592.","journal-title":"World J Surg"},{"key":"43_CR7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archsurg.1992.01420040088015","volume":"127","author":"JL Pasieka","year":"1992","unstructured":"Pasieka JL, McLeod MK, Thompson NW, et al: Surgical approach to insulinomas. assessing the need for preoperative localization. Arch Surg 1992, 127: 442\u2013447.","journal-title":"Arch Surg"},{"key":"43_CR8","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1111\/j.1572-0241.2000.02480.x","volume":"95","author":"MA Anderson","year":"2000","unstructured":"Anderson MA Carpentar S, Thompson NW, et al: Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000, 95: 2271\u20132277.","journal-title":"Am J Gastroenterol"},{"key":"43_CR9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/BF00353743","volume":"18","author":"DS O\u2019Riordain","year":"1994","unstructured":"O\u2019Riordain DS, O\u2019Brien T, van Heerden JA et al.: Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg 1994, 18: 488\u2013493; discussion 493\u2013494.","journal-title":"World J Surg"},{"key":"43_CR10","first-page":"998","volume":"110","author":"MJ Demeure","year":"1991","unstructured":"Demeure MJ, Klonoff DC, Karam JH, et al: Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. Surgery 1991, 110: 998\u20131004; discussion 1004\u20131005.","journal-title":"Surgery"},{"key":"43_CR11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0950-3528(96)90019-6","volume":"10","author":"S Frankton","year":"1990","unstructured":"Frankton S, Bloom SR: Gastrointestinal endocrine tumours. Glucagonomas. Baillieres Clin Gastroenterol 1990, 10: 697\u2013705.","journal-title":"Baillieres Clin Gastroenterol"},{"key":"43_CR12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0306-9877(80)90125-5","volume":"6","author":"DF Horrobin","year":"1980","unstructured":"Horrobin DF, Cunnane SC: Interactions between zinc, essential fatty acids and prostaglandins: relevance to acrodermatitis enteropathica, total parenteral nutrition, the glucagonoma syndrome, diabetes, anorexia nervosa, and sickle cell anemia. Med Hypotheses 1980, 6: 277\u2013296.","journal-title":"Med Hypotheses"},{"key":"43_CR13","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0748-7983(98)93716-7","volume":"24","author":"Rassi Z El","year":"1998","unstructured":"El Rassi Z, Partensky C, Valette PJ, et al: Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long-acting somatostatin and surgical resection. Report of three cases. Eur J Surg Oncol 1998, 24: 562\u2013567.","journal-title":"Eur J Surg Oncol"},{"key":"43_CR14","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/archsurg.1994.01420330079015","volume":"129","author":"HT Debas","year":"1994","unstructured":"Debas HT, Mulvihill SJ: Neuroendocrine gut neoplasms. Important lessons from uncommon tumors. Arch Surg 1994, 129: 965\u2013971; discussion 971\u2013972.","journal-title":"Arch Surg"},{"key":"43_CR15","first-page":"191","volume":"17","author":"M Rothmund","year":"1991","unstructured":"Rothmund M, Stinner B, Arnold R: Endocrine pancreatic carcinoma. Eur f Surg Oncol 1991, 17: 191\u2013199.","journal-title":"Eur f Surg Oncol"},{"key":"43_CR16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cncr.10195","volume":"94","author":"H Shojamanesh","year":"2002","unstructured":"Shojamanesh H, Gibril F, Louie A et al: Prospective study of the anti-tumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002, 94: 331\u2013343.","journal-title":"Cancer"},{"key":"43_CR17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0960-7404(03)00035-5","volume":"12","author":"JA Norton","year":"2003","unstructured":"Norton JA, Jensen RT: Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). Surg Oncol 2003, 12: 145\u2013151.","journal-title":"Surg Oncol"},{"key":"43_CR18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/bjs.1800800528","volume":"80","author":"S Cheslyn-Curtis","year":"1993","unstructured":"Cheslyn-Curtis S, Sitaram V, Williamson RC, et al: Management of non-functioning neuroendocrine tumours of the pancreas. Br J Surg 1993, 80: 625\u2013627.","journal-title":"Br J Surg"},{"key":"43_CR19","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/000313480006601206","volume":"66","author":"BD Matthews","year":"2000","unstructured":"Matthews BD, Heniford BT, Reardon PR, et al: Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas. Am Surg 2000, 66: 1116\u20131122; discussion 1122\u20131123.","journal-title":"Am Surg"},{"key":"43_CR20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s002689900029","volume":"20","author":"M Dusmet","year":"1996","unstructured":"Dusmet M, McKneally M: Pulmonary and thymic carcinoid tumors. World J Surg 1996, 20: 189\u2013195.","journal-title":"World J Surg"},{"key":"43_CR21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0003-4975(92)91139-Z","volume":"54","author":"D Harpole","year":"1992","unstructured":"Harpole D, Feldman J, Buchanan S, et al: Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg 1992, 54: 50\u201355.","journal-title":"Ann Thorac Surg"},{"key":"43_CR22","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/0016-5085(93)90266-F","volume":"104","author":"G Rindi","year":"1993","unstructured":"Rindi G, Luinetti O, Cornaggia M, et al.: Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a dinicopathologic study. Gastroenterology 1993, 104: 994\u20131006.","journal-title":"Gastroenterology"},{"key":"43_CR23","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/archsurg.1995.01430030020003","volume":"130","author":"I Modlin","year":"1995","unstructured":"Modlin I, Gilligan C, Lawton G, et al.: Gastric carcinoids: the Yale experience. Arch Surg 1995, 130: 250\u2013255; discussion 255\u2013256.","journal-title":"Arch Surg"},{"key":"43_CR24","first-page":"1046","volume":"104","author":"F Eckhauser","year":"1988","unstructured":"Eckhauser F, Lloyd R, Thompson N, et al.: Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report. Surgery 1988, 104: 1046\u20131053.","journal-title":"Surgery"},{"key":"43_CR25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/0016-5085(92)90787-Y","volume":"102","author":"BI Hirschowitz","year":"1992","unstructured":"Hirschowitz BI, Griffith J, Pellegrin D, Cummings O: Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992, 102: 1409\u20131418.","journal-title":"Gastroenterology"},{"key":"43_CR26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJM200008243430805","volume":"343","author":"P Tomassetti","year":"2000","unstructured":"Tomassetti P, Migliori M, Caletti G, et al: Treatment of type-II gastric carcinoid tumors with somatostatin analogs. N Engl J Med 2000, 343: 551\u2013554.","journal-title":"N Engl J Med"},{"key":"43_CR27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/(SICI)1097-0142(19970315)79:6<1086::AID-CNCR5>3.0.CO;2-E","volume":"79","author":"A Burke","year":"1997","unstructured":"Burke A, Thomas R, Elsayed A, Sobin L: Carcinoids of the jejunum and ileum: an immunohistochemical and dinicopathologic study of 167 cases. Cancer 1997, 79: 1086\u20131093.","journal-title":"Cancer"},{"key":"43_CR28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/02841869109092416","volume":"30","author":"G Akerstrom","year":"1991","unstructured":"Akerstrom G, Makridis C, Johansson H: Abdominal surgery in patients with midgut cardnoid tumors [review]. Acta Oncol 1991, 30: 547\u2013553.","journal-title":"Acta Oncol"},{"key":"43_CR29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00000658-199304000-00010","volume":"217","author":"A Roggo","year":"1993","unstructured":"Roggo A, Wood W, Ottinger L: Carcinoid tumors of the appendix. Ann Surg 1993, 217: 385\u2013390.","journal-title":"Ann Surg"},{"key":"43_CR30","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1056\/NEJM198712313172704","volume":"317","author":"C Moertel","year":"1987","unstructured":"Moertel C, Weiland L, Nagorney D, Dockerty M: Cardnoid tumors of the appendix: treatment and prognosis. N Engl J Med 1987, 317: 1699\u20131701. Large retrospective surgical series defining the surgical management of appendiceal carcinoid tumors.","journal-title":"N Engl J Med"},{"key":"43_CR31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/BF02050318","volume":"35","author":"A Jetmore","year":"1992","unstructured":"Jetmore A, Ray J, Gathright J, et al.: Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum 1992, 35: 717\u2013725.","journal-title":"Dis Colon Rectum"},{"key":"43_CR32","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1294::AID-CNCR4>3.0.CO;2-H","volume":"79","author":"A Koura","year":"1997","unstructured":"Koura A, Giacco G, Curley S, et al.: Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer 1997, 79: 1294\u20131298.","journal-title":"Cancer"},{"key":"43_CR33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00000658-199001000-00012","volume":"211","author":"P Sauven","year":"1990","unstructured":"Sauven P, Ridge J, Quan S, Sigurdson E: Anorectal carcinoid tumors: is aggressive surgery warranted? Ann Surg 1990, 211: 67\u201371.","journal-title":"Ann Surg"},{"issue":"Suppl 6B","key":"43_CR34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-9343(86)90583-8","volume":"81","author":"J Feldman","year":"1986","unstructured":"Feldman J, O\u2019Dirisio T: Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 1986, 81(Suppl 6B): 41\u201348.","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"43_CR35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000051853","volume":"62","author":"B Eriksson","year":"2000","unstructured":"Eriksson B, Oberg K, Stridsberg M: Tumor markers in neuroendocrine tumors. Digestion 2000, 62(Suppl 1): 33\u201338.","journal-title":"Digestion"},{"key":"43_CR36","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1008215730767","volume":"8","author":"E Janson","year":"1997","unstructured":"Janson E, Holmberg L, Stridsberg M, et al.: Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997, 8: 685\u2013690.","journal-title":"Ann Oncol"},{"key":"43_CR37","first-page":"5969","volume":"50","author":"J Reubi","year":"1990","unstructured":"Reubi J, Kvols L, Waser B, et al.: Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of cardnoids and islet cell carcinomas. Cancer Res 1990, 50: 5969\u20135977.","journal-title":"Cancer Res"},{"key":"43_CR38","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","volume":"315","author":"L Kvols","year":"1986","unstructured":"Kvols L, Moertel C, O\u2019Connell M, et al.: Treatment of the malignant cardnoid syndrome: evaluation of a long-acting somatostatin analog. N Engl J Med 1986, 315: 663\u2013666.","journal-title":"N Engl J Med"},{"key":"43_CR39","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","volume":"17","author":"J Rubin","year":"1999","unstructured":"Rubin J, Ajani J, Schirmer W, et al: Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant cardnoid syndrome. J Clin Oncol 1999, 17: 600\u2013606. Randomized trial demonstrating the efficacy of a longacting octreotide formulation in the management of carcinoid syndrome.","journal-title":"J Clin Oncol"},{"key":"43_CR40","first-page":"519","volume":"30","author":"K Oberg","year":"1991","unstructured":"Oberg K, Eriksson B: The role of interferons in the management of carcinoid tumors. Br J Haematol 1991, 30: 519\u2013522.","journal-title":"Br J Haematol"},{"key":"43_CR41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841869309083916","volume":"32","author":"E Janson","year":"1993","unstructured":"Janson E, Oberg K: Long term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993, 32: 225\u2013229.","journal-title":"Acta Oncol"},{"key":"43_CR42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/1097-0142(19910201)67:3<547::AID-CNCR2820670302>3.0.CO;2-J","volume":"67","author":"M Valimaki","year":"1991","unstructured":"Valimaki M, Jarvinen H, Salmela P, et al: Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 1991, 67: 547\u2013549.","journal-title":"Cancer"},{"key":"43_CR43","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"S Faiss","year":"2003","unstructured":"Faiss S, Pape U, Bohmig M, et al: Prospective, randomized multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003, 21: 2689\u20132896. Randomized trial demonstrating radiologic regression rates in patients treated with a somatostatin analog, INF, or combination of the two drugs.","journal-title":"J Clin Oncol"},{"key":"43_CR44","first-page":"327","volume":"2","author":"C Moertel","year":"1979","unstructured":"Moertel C, Hanley J: Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979, 2: 327\u2013334.","journal-title":"Cancer Clin Trials"},{"key":"43_CR45","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.1984.2.11.1255","volume":"2","author":"P Engstrom","year":"1984","unstructured":"Engstrom P, Lavin P, Moertel C: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984, 2: 1255\u20131259. Randomized trial demonstrating modest efficacy but significant toxicity associated with streptozocin\/5FU in patients with advanced carcinoid tumor.","journal-title":"J Clin Oncol"},{"key":"43_CR46","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","volume":"326","author":"C Moertel","year":"1992","unstructured":"Moertel C, Lefkopoulo M, Lipsitz S, et al: Streptozocindoxorubidn, stretpozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992, 326: 519\u2013523. Randomized trial demonstrating efficacy of streptozocin and doxorubicin in the treatment of PETs.","journal-title":"N Engl J Med"},{"key":"43_CR47","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P","volume":"86","author":"P Cheng","year":"1999","unstructured":"Cheng P, Saltz L: Failure to confirm major objective antitumor activity of streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999, 86: 944\u2013948.","journal-title":"Cancer"},{"key":"43_CR48","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/1097-0142(19940301)73:5<1505::AID-CNCR2820730530>3.0.CO;2-V","volume":"73","author":"R Bukowski","year":"1994","unstructured":"Bukowski R, Tangen C, Petserson R, et al: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 1994, 73: 1505\u20131508.","journal-title":"Cancer"},{"key":"43_CR49","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1023\/A:1011632713360","volume":"12","author":"R Ramanthan","year":"2001","unstructured":"Ramanthan R, Cnaan A, Hahn R, et al: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell cardnoma. Study of the Eastern Cooperative Oncology Group E-6282. Ann Oncol 2001, 12: 1139\u20131143.","journal-title":"Ann Oncol"},{"key":"43_CR50","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdf064","volume":"13","author":"E Bajetta","year":"2002","unstructured":"Bajetta E, Ferrari L, Procopio G, et al: Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumors. Ann Oncol 2002, 13: 614\u2013621.","journal-title":"Ann Oncol"},{"key":"43_CR51","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/1097-0142(20010415)91:8<1543::AID-CNCR1163>3.0.CO;2-N","volume":"91","author":"S Ansell","year":"2001","unstructured":"Ansell S, Pitot H, Burch P, et al: A phase II study of high-dose paditaxel in patients with advanced neuroendocrine tumors. Cancer 2001, 91: 1543\u20131548.","journal-title":"Cancer"},{"key":"43_CR52","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1081\/CNV-200029058","volume":"22","author":"M Kulke","year":"2004","unstructured":"Kulke M, Kim H, Stuart K, et al.: Phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest 2004, 22: 353\u2013359.","journal-title":"Cancer Invest"},{"key":"43_CR53","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.20466","volume":"101","author":"MH Kulke","year":"2004","unstructured":"Kulke MH, Kim H, Clark JW, et al.: A Phase II study of gemcitabine for metastatic neuroendocrine tumors. Cancer 2004, 101: 934\u2013939.","journal-title":"Cancer"},{"key":"43_CR54","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9610(99)80107-X","volume":"169","author":"F Que","year":"1995","unstructured":"Que F, Nagorney D, Batts K, et al.: Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995, 169: 36\u201342; discussion 42\u201343.","journal-title":"Am J Surg"},{"key":"43_CR55","first-page":"1091","volume":"108","author":"G McEntee","year":"1990","unstructured":"McEntee G, Nagorney D, Kvols L, et al.: Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990, 108: 1091\u20131096.","journal-title":"Surgery"},{"key":"43_CR56","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.surg.2003.07.025","volume":"134","author":"J Norton","year":"2003","unstructured":"Norton J, Warren R, Kelly M: Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003, 134: 1057\u20131065.","journal-title":"Surgery"},{"key":"43_CR57","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00000658-199704000-00002","volume":"225","author":"H Lang","year":"1997","unstructured":"Lang H, Oldhafer K, Weimann A, et al.: Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997, 225: 347\u2013354.","journal-title":"Ann Surg"},{"key":"43_CR58","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00000658-199704000-00003","volume":"225","author":"Y LeTreut","year":"1997","unstructured":"LeTreut Y, Delpero J, Dousset B, et al.: Results of liver transplantation in the treatment of metastatic neuroendocrine tumors: a 31-case French multicentric report. Ann Surg 1997, 225: 355\u2013364.","journal-title":"Ann Surg"},{"key":"43_CR59","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/s00268-002-6631-y","volume":"26","author":"M Olausson","year":"2002","unstructured":"Olausson M, Friman S, Cahlin C, et al.: Indications and results of liver transplantation in patients with neuroendocrine tumors. World J Surg 2002, 26: 998\u20131004.","journal-title":"World J Surg"},{"key":"43_CR60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00001622-199901000-00009","volume":"11","author":"A Venook","year":"1999","unstructured":"Venook A: Embolization and chemoembolization therapy for neuroendocrine tumors. Curr Opin Oncol 1999, 11: 38\u201341.","journal-title":"Curr Opin Oncol"},{"key":"43_CR61","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00130404-200307000-00008","volume":"9","author":"S Gupta","year":"2003","unstructured":"Gupta S, Yao J, Ahrar K, et al.: Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the MD Anderson experience. Cancer 2003, 9: 261\u2013267.","journal-title":"Cancer"},{"key":"43_CR62","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/snuc.2002.31027","volume":"32","author":"M Jong De","year":"2002","unstructured":"De Jong M, Valkema R, Jamar F, et al.: Somatostatinreceptor targeted radionudeotide therapy of tumors: predinical and dinical findings. Semin Nucl Med 2002, 32: 133\u2013140.","journal-title":"Semin Nucl Med"},{"key":"43_CR63","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/snuc.2002.31565","volume":"32","author":"I Virgolini","year":"2002","unstructured":"Virgolini I, Britton K, Buscombe J, et al: In and Y-DOTA-Lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002, 32: 148\u2013155.","journal-title":"Semin Nucl Med"},{"key":"43_CR64","first-page":"610","volume":"43","author":"C Waldherr","year":"2002","unstructured":"Waldherr C, Pless M, Maecke H, et al: Tumor response and dinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC). J Nucl Med 2002, 43: 610\u2013616.","journal-title":"J Nucl Med"},{"key":"43_CR65","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00259-003-1117-1","volume":"30","author":"F Jamar","year":"2003","unstructured":"Jamar F, Barone R, Mathieu I, et al: 86Y-DOTA0-D-Phe 1-Tyr3-octreotide (SMT487)-a phase I dinical study: pharmacokinetics, biodistribution, and renal protective effect of different regimens of amino add co-infusion. Eur J Nuc Med Mol Imaging 2003, 30: 510\u2013518.","journal-title":"Eur J Nuc Med Mol Imaging"},{"key":"43_CR66","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s002590100574","volume":"28","author":"D Kwekkeboom","year":"2001","unstructured":"Kwekkeboom D, Bakker W, Kooij P, et al: 177Lu-DOTA,Tyr3 octreotate: comparison with [111In-DTPA] octreotide in patients. Eur J Nucl Med 2001, 28: 1319\u20131325.","journal-title":"Eur J Nucl Med"},{"key":"43_CR67","unstructured":"Hobday T, Rubin J, Goldberg R, et al: Molecular markers in metastatic gastrointestinal neuroendocrine tumors. Proc ASCO 2003, 22."},{"key":"43_CR68","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.284.5415.808","volume":"284","author":"G Bergers","year":"1999","unstructured":"Bergers G, Javaherian K, Lo K, et al: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999, 284: 808\u2013812.","journal-title":"Science"},{"key":"43_CR69","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1200\/JCO.2002.02.082","volume":"20","author":"J Eder","year":"2002","unstructured":"Eder J, Supko J, Clark J, et al: Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002, 20: 3772\u20133784.","journal-title":"J Clin Oncol"},{"key":"43_CR70","unstructured":"Kulke M, Bergsland E, Ryan D, et al: A phase II openlabel, safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors [abstract]. Proc ASCO 2003, 22."},{"key":"43_CR71","unstructured":"Kulke M, Ryan D, Stuart K, et al: A phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. Presented in abstract form at the Chemotherapy Foundation Symposium XXI, New York, NY [abstract]. Proc ASCO 2003."},{"key":"43_CR72","doi-asserted-by":"crossref","unstructured":"Yao JC, Ng C, Hoff PM, et al: Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced cardnoid treated with bevadzumab. Proc ASCO 2005, A4007.","DOI":"10.1200\/jco.2005.23.16_suppl.4007"},{"key":"43_CR73","first-page":"A1491","volume":"22","author":"J Yao","year":"2003","unstructured":"Yao J, Yeung S, Rashid A, et al: Early results of a phase II trial of imatinib in patients with advanced cardnoid tumor. Proc ASCO 2003, 22: A1491.","journal-title":"Proc ASCO"},{"key":"43_CR74","first-page":"A765","volume":"22","author":"L Rosen","year":"2003","unstructured":"Rosen L, Mulay M, Long J, et al: Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc ASCO 2003, 22: A765.","journal-title":"Proc ASCO"},{"key":"43_CR75","doi-asserted-by":"crossref","unstructured":"Kulke M, Lenz HJ, Meropol NJ, et al.: A phase 2 study to evaluate the efficacy and safety of SU 11248 in patients with unresectable neuroendocrine tumors. Proc ASCO 2005: A4008.","DOI":"10.1200\/jco.2005.23.16_suppl.4008"},{"key":"43_CR76","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1002\/1097-0142(19871215)60:12<2891::AID-CNCR2820601207>3.0.CO;2-6","volume":"60","author":"R Bukowski","year":"1987","unstructured":"Bukowski R, Johnson K, Petserson R, et al: A phase II trial of combination chemotherapy in patients with metastatic cardnoid tumors. Cancer 1987, 60: 2891\u20132895.","journal-title":"Cancer"},{"key":"43_CR77","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","volume":"303","author":"CG Moertel","year":"1980","unstructured":"Moertel CG, Hanley JA, Johnson LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980, 303: 1189\u20131194.","journal-title":"N Engl J Med"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-005-0043-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-005-0043-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-005-0043-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T21:18:23Z","timestamp":1683926303000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-005-0043-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["43"],"URL":"https:\/\/doi.org\/10.1007\/s11864-005-0043-9","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}